Serial Number 98609776
730

Registration Progress

Application Filed
Jun 20, 2024
Under Examination
Apr 1, 2025
Approved for Publication
Feb 4, 2025
Published for Opposition
Feb 4, 2025
Registered

Trademark Image

Basic Information

Serial Number
98609776
Filing Date
June 20, 2024
Published for Opposition
February 4, 2025
Drawing Code
2

Status Summary

Current Status
Active
Status Code
730
Status Date
Sep 24, 2025
Application
Pending
Classes
005

Rights Holder

Fresenius Kabi Deutschland GmbH

16
Address
Else-Kröner-Str. 1
Bad Homburg 61352
DE

Ownership History

Fresenius Kabi Deutschland GmbH

Original Applicant
16
Bad Homburg DE

Fresenius Kabi Deutschland GmbH

Owner at Publication
16
Bad Homburg DE

Legal Representation

Attorney
Scott D. Woldow

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

13 events
Date Code Type Description Documents
Sep 24, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 24, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Sep 24, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 24, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Apr 1, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 4, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 4, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 29, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 15, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 13, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 12, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 12, 2025 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Jun 20, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Pharmaceutical preparations for the treatment of autoimmune diseases, illnesses and conditions; Pharmaceutical preparations, namely, immunosuppressants; Pharmaceutical preparations for the treatment of plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and active enthesitis related arthritis, Crohn's disease, ulcerative colitis, hidradenitis colitis, hidradenitis suppurativa and non-infectious uveitis; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Biologics, namely, biological preparations for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Biologics, namely, biological preparations for the treatment of ankylosing spondylitis; Biological preparations for the treatment of and reducing signs and symptoms in adult patients with active ankylosing spondylitis; Protein therapeutics, namely, protein supplements; Pharmaceutical preparations for treating ankylosing spondylitis; Pharmaceutical preparations for the treatment of and for reducing signs and symptoms in adult patients with active ankylosing spondylitis

Additional Information

Design Mark
The mark consists of a stylized globe.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005